Mark J. Selby
89Patents
18h-index
98Co-inventors
87Inventor score
Filing activity: May 12, 1995 → May 11, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8008449B2 | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics | Emerging Cross-Sectional Technologies | 812 | Active |
| US7943743B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 541 | Active |
| US8779105B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 204 | Active |
| US8383796B2 | Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 148 | Active |
| US9084776B2 | Methods for treating cancer using anti-PD-1 antibodies | Emerging Cross-Sectional Technologies | 134 | Active |
| US9492540B2 | Methods for treating cancer using anti-PD-1 antibodies | Emerging Cross-Sectional Technologies | 116 | Active |
| US9358289B2 | Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies | Emerging Cross-Sectional Technologies | 112 | Active |
| US9387247B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 98 | Active |
| US9492539B2 | Monoclonal antibodies to Programmed Death 1 (PD-1) | Emerging Cross-Sectional Technologies | 96 | Active |
| US9102725B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 90 | Active |
| US9273135B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 77 | Active |
| US6602705B1 | Expression of HIV polypeptides and production of virus-like particles | Chemistry; Metallurgy | 73 | Expired |
| US9580507B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 47 | Active |
| US9228016B2 | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof | Physics | 31 | Active |
| US9580505B2 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) | Emerging Cross-Sectional Technologies | 31 | Active |
| US10441655B2 | Monoclonal antibodies to programmed death 1 (PD-1) | Emerging Cross-Sectional Technologies | 21 | Active |
| US6096505A | Noncloning technique for expressing a gene of interest | Chemistry; Metallurgy | 21 | Expired |
| US10344089B2 | Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof | Chemistry; Metallurgy | 20 | Active |
| US6562346B1 | Activation of HCV-specific T cells | Chemistry; Metallurgy | 18 | Expired |
| US6986892B1 | Immunogenic Hepatitis C virus non-structural polypeptides | Chemistry; Metallurgy | 18 | Expired |
| US10251945B2 | Anti-ICOS agonist antibodies and uses thereof | Chemistry; Metallurgy | 17 | Active |
| US6121020A | Hepatitis C E1 and E2 polypeptides and methods of obtaining the same | Chemistry; Metallurgy | 14 | Expired |
| US6521423B1 | Intracellular production of Hepatitis C E2 polypeptides | Emerging Cross-Sectional Technologies | 13 | Expired |
| US10196445B1 | Ipilimumab variant with enhanced ADCC | Chemistry; Metallurgy | 12 | Active |
| US9745379B2 | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof | Physics | 11 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.